Helicobacter Pylori Infections – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Helicobacter Pylori Infections Market Outlook

Thelansis’s “Helicobacter Pylori Infections Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Helicobacter Pylori Infections treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Helicobacter Pylori Infections Overview

Helicobacter pylori (H. pylori) is a microaerophilic, flagellated, Gram-negative bacterium with a helix-shaped morphology. It can transform from a spiral to a coccoid shape, believed to aid its survival in the gastric environment of the host. H. pylori is implicated in causing acute gastritis, characterized by infiltrating neutrophils into the foveolar and surface epithelium, along with degenerative changes. In the majority of infected individuals, H. pylori establishes a persistent infection. Prolonged H. pylori infection leads to chronic gastritis, presenting as various pathological conditions. This form of gastritis associated with H. pylori can be categorized into distinct clinical phenotypes. Most H. pylori-infected individuals develop nonatrophic pangastritis, which does not predispose them to peptic ulcers or gastric atrophy. The development of gastroduodenal diseases appears to be influenced by bacterial and host factors. In the United States, up to 16% of H. pylori-infected individuals experience duodenal ulcers and chronic active gastritis. Interestingly, there is an inverse relationship or paradox between the incidence of duodenal ulcer disease and gastric adenocarcinoma. Several medications have received approval from the US Food and Drug Administration (FDA) for treating H. pylori infection. These include Voquezna Triple Pak (containing vonoprazan, amoxicillin, and clarithromycin), Voquezna Dual Pak (containing vonoprazan and amoxicillin), Talicia (containing omeprazole magnesium, amoxicillin, and rifabutin), Prilosec (offered in delayed-release oral suspension and containing omeprazole magnesium), as well as Nexium (available as esomeprazole magnesium) and Nexium I.V (intravenous esomeprazole sodium).

• Globally, the prevalence of Helicobacter pylori infection is approximately 50%, with higher rates of around 80%-90% in developing countries and lower rates of about 35%-40% in the United States.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: